Generic Name and Formulations:
Desonide 0.05%; crm.
Encore Dermatology, Inc.
Indications for TRIDESILON:
Apply thin film 2–4 times daily. Do not occlude. Reevaluate if no improvement after 2 weeks.
Treat infection if present or develop; discontinue until infection controlled. Systemic absorption increased by altered skin barrier, inflamed skin, prolonged use, application to large surface area, or use of occlusive dressings. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, or irritation occurs. Do not use near eyes, or if hypersensitivity to corticosteroid, or pre-existing skin atrophy. Allergic contact dermatitis. Pregnancy (Cat.C). Nursing mothers.
Pruritus, pain, folliculitis, rash, peripheral edema, pustular rash, sweating, erythema, irritation, burning, hypergylcemia, liver function abnormality; HPA axis suppression (esp. in children).
Neurology Advisor Articles
- Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Gender Differences in the Epidemiology of Migraine
- Changes in Glucose Regulation in Parkinson Disease
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Locally Asymptomatic Ischemic Stroke May Present as Migraine Aura
- Associations Identified Between Stroke Severity, Recovery of Visuospatial Neglect
- Action Tremor May Have Central Origin in Motor Neuron Disease
- Characteristics Affecting Health-Related Quality of Life in RRMS, Progressive MS
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd